uniQure N.V.

NasdaqGS:QURE Lagerbericht

Marktkapitalisierung: US$213.6m

uniQure Management

Management Kriterienprüfungen 2/4

uniQure's CEO ist Matt Kapusta , ernannt in Dec 2016, hat eine Amtszeit von 7.5 Jahren. Die jährliche Gesamtvergütung beträgt $6.58M , bestehend aus 9.6% Gehalt und 90.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.67% der Aktien des Unternehmens, im Wert von $1.53M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 7.4 Jahre.

Wichtige Informationen

Matt Kapusta

Geschäftsführender

US$6.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts9.6%
Amtszeit als Geschäftsführer7.5yrs
Eigentum des Geschäftsführers0.7%
Durchschnittliche Amtszeit des Managements2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.8yrs

Jüngste Management Updates

Recent updates

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15
A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27
Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02
uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28
Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01
News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure: Betting On Hemophilia-B Cure

Jan 18

UniQure: Leading Gene Therapy Company

Nov 06

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Oct 24
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

How We Are Playing UniQure

Oct 04

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Matt Kapusta im Vergleich zu den Einnahmen von uniQure verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$297m

Dec 31 2023US$7mUS$635k

-US$308m

Sep 30 2023n/an/a

-US$228m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$157m

Dec 31 2022US$6mUS$609k

-US$127m

Sep 30 2022n/an/a

-US$125m

Jun 30 2022n/an/a

-US$114m

Mar 31 2022n/an/a

US$324m

Dec 31 2021US$5mUS$583k

US$330m

Sep 30 2021n/an/a

US$321m

Jun 30 2021n/an/a

US$303m

Mar 31 2021n/an/a

-US$139m

Dec 31 2020US$4mUS$585k

-US$125m

Sep 30 2020n/an/a

-US$166m

Jun 30 2020n/an/a

-US$136m

Mar 31 2020n/an/a

-US$124m

Dec 31 2019US$4mUS$548k

-US$124m

Sep 30 2019n/an/a

-US$105m

Jun 30 2019n/an/a

-US$103m

Mar 31 2019n/an/a

-US$92m

Dec 31 2018US$3mUS$502k

-US$83m

Sep 30 2018n/an/a

-US$90m

Jun 30 2018n/an/a

-US$78m

Mar 31 2018n/an/a

-US$78m

Dec 31 2017US$4mUS$468k

-US$79m

Vergütung im Vergleich zum Markt: MattDie Gesamtvergütung ($USD6.58M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.58M).

Entschädigung vs. Einkommen: MattDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Matt Kapusta (52 yo)

7.5yrs

Amtszeit

US$6,584,919

Vergütung

Mr. Matthew Craig Kapusta, also known as Matt, served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until September 25, 2023. He has been the Chief Executive Officer of uniQure N.V...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Matthew Kapusta
CEO & Executive Director7.5yrsUS$6.58m0.67%
$ 1.4m
Christian Klemt
CFO, Principal Financial Officer & GM of Amsterdam Site3yrsUS$2.12m0.16%
$ 333.8k
Pierre Caloz
Chief Operating Officer3.1yrsUS$2.81m0.081%
$ 172.5k
Richard Porter
Chief Business & Scientific Officerless than a yearUS$2.62m0.068%
$ 146.2k
Jeannette Potts
Chief Legal & Compliance Officer and Corporate Secretary1.1yrsUS$2.54m0.022%
$ 48.0k
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germanyno datakeine Datenkeine Daten
Tamara Tugal
Business Development Director16yrskeine Datenkeine Daten
Maria Cantor
Chief Corporate Affairs Officer2.3yrsUS$1.22mkeine Daten
Amin Abujoub
Chief Quality Officer1.4yrskeine Datenkeine Daten
Walid Abi-Saab
Chief Medical Officerless than a yearkeine Datenkeine Daten
Eileen Sawyer
Vice President of Global Medical Affairsno datakeine Datenkeine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: QUREDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Matthew Kapusta
CEO & Executive Director9.4yrsUS$6.58m0.67%
$ 1.4m
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany9.8yrskeine Datenkeine Daten
Leonard Post
Independent Non-Executive Director4yrsUS$412.46k0.033%
$ 70.4k
Michael Hayden
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Katherine High
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Jack Kaye
Independent Non-Executive Director8yrsUS$424.96k0.013%
$ 28.6k
Jesús Prieto
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Robin Ali
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Madhavan Balachandran
Independent Non-Executive Director6.8yrsUS$412.46k0.049%
$ 104.5k
Jeremy Springhorn
Independent Non-Executive Director6.8yrsUS$424.96k0.049%
$ 104.5k
David Meek
Independent Chairman of the Board6yrsUS$444.96k0.042%
$ 89.1k
Robert Gut
Non-Executive Director5.7yrsUS$404.96k0.091%
$ 194.3k

6.8yrs

Durchschnittliche Betriebszugehörigkeit

71yo

Durchschnittliches Alter

Erfahrener Vorstand: QUREDie Vorstandsmitglieder gelten als erfahren (7.4 Jahre durchschnittliche Amtszeit).